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Gene profilesThis review describes the developments in the radiation treatment of breast cancer based on some ran-
domized European trials during the past decades. It will focus on the relevance of long term follow-up in
breast cancer patients, starting with the surprising and important change in treatment results during
follow-up shown in a locally advanced breast cancer trial. Breast conserving therapy (BCT) in stage I
and II breast cancer was explored and tested in a randomized trial to prove equivalence between BCT
and mastectomy. The positive outcome led to trials in breast conserving therapy with lower doses and
partial breast irradiation. Finally the need for finding genetic profiles for predicting treatment response
will be addressed in a trial with preoperative partial breast irradiation.
 2016 The Author. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 121 (2016) 348–356
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).The role of radiotherapy for breast cancer has changed dramat-
ically during the last decades. Initially mastectomy was the stan-
dard care for operable breast cancer and irradiation was used
mostly in an attempt to palliate inoperable disease or for postmas-
tectomy irradiation. The development of Co60 apparatus and linear
accelerators allowed for delivery of higher tumour doses herewith
obtaining tumour control in locally advanced breast cancer. The
encouraging results in obtaining local control in advanced breast
cancer have led to a trial exploring the value of adjuvant systemic
treatment in these patients. The surprising change in the treatment
results during follow-up of the locally advanced breast cancer trial
will be addressed. These patients were treated with irradiation
alone or in combination with systemic treatment. The encouraging
results by obtaining tumour control with irradiation in these
advanced tumours has led to exploration of breast conserving ther-
apy (BCT) in stage I and II breast cancer. In order to prove equiva-
lence BCT was compared with mastectomy in a randomized trial.
The positive outcome of this trial led to subsequent studies in
breast conserving therapy aiming to further improve local control.
These trials have demonstrated a major improvement in local curerates in recent decades. Therefore, several strategies for de-
escalation in low-risk patients are currently under investigation,
such as partial breast irradiation instead of whole breast irradia-
tion or omission of radiotherapy. This review will conclude with
describing the selection of patients for preoperative accelerated
partial breast irradiation, aiming at reducing toxicity and at the
same time providing information on the response of radiotherapy.
Currently, clinicopathological factors are used for patient selection,
but gene expression profiling could be of additive value.Locally advanced breast cancer: the EORTC trial 10792 trial
The EORTC 10792 trial in locally advanced breast cancer was
initiated in 1979 at a time when systemic therapy with hormones
or chemotherapy was mostly given for distant metastases in breast
cancer patients. It aimed to assess the possible contribution of
adjuvant hormonal therapy (HT) or chemotherapy (CT) on both
local control and survival. 410 Patients with inoperable breast can-
cer were randomized between radiotherapy (RT) alone versus RT
with HT, and RT with HT and CT [1]. The results demonstrated that
permanent tumour control in advanced breast cancer could be
achieved without surgery, with radiotherapy alone or in combina-
tion with systemic treatment. It was the first randomized trial that
showed improved local control by adding chemotherapy or hor-
monal therapy to radiotherapy in breast cancer (Fig. 1). Interim
analysis during the course of the trial showed that there was a
major benefit in terms of survival in favour of adjuvant CT. The
Fig. 1. IMPACT OF ADJUVANT chemotherapy and, or hormonotherapy on locoregional recurrence rate after radiotherapy (xrt) for locally advanced breast cancer. Adapted
from Ref. [1].
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pants became aware of this benefit. Consequently, the trial was
closed earlier than planned. At the time of the closure of this trial
a significant improvement of survival was observed in patients
who received CT (P = .004); nevertheless, with a longer follow-up
this effect disappeared (P > .05). Initially, HT did not appear to
improve survival (P = .16); but in the latest analysis, a significant
improvement of survival was seen (P = .02) (Fig. 2, Addendum
Fig. A1). It is also important to mention that a consistent 25%
reduction in the death hazard ratio has been seen at all evaluations
since trial closure in patients who received HT. The improvement
in survival obtained with HT became therefore apparent only after
long-term follow-up evaluation. The best survival results were
observed in patients who received RT, HT, and CT (P = .02), with
a reduction of 35% in the death hazard ratio [1,2]. As the improved
survival rates were not influenced by age we concluded that even
young inoperable breast cancer patients might benefit from HT,
while at the time of publication adjuvant hormonal therapy was
only prescribed for the postmenopausal patient. This trial taught
us the potential danger of drawing conclusions based on only shortFig. 2. Reversal of fortune: change in P values during and after finishing the locally
advanced breast cancer trial. Adapted from Ref. [1].term follow-up data. Another lesson was that a trial statistician
should not unblind the trial data, and should certainly not inform
trial participants on the possible outcome, as that was of major
influence on the accrual of patients. As a result, strict rules have
since been established for randomized trials for independent data
monitoring committees (IDMC) for evaluation of treatment toxicity
and efficacy including futility analyses to prevent selection bias or
change in accrual during the course of a trial.Mastectomy versus BCT: the EORTC trial 10801
Up to the 1980s a radical mastectomy, usually the Halsted, or
modified radical mastectomy (MRM) such as the Patey or Madden
procedure, was the standard treatment for most patients regard-
less of the stage of their disease. The above mentioned findings
in preserving the breast in patients with locally advanced breast
cancer together with the expertise in French radiotherapy centres
led to the exploration of breast-conserving therapy (BCT) [3]. How-
ever, an unacceptably high level of local recurrences in patients
after BCT was observed in the Guys hospital trial [4]. The prelimi-
nary results of 2 clinical trials in the treatment of tumours 2 cm or
smaller [5,6] showed much more favourable results than observed
in the Guy’s trial. Evidence on the long term results especially in
patients with stage II disease (tumours larger than 2 cm and/or
positive lymph nodes) was lacking at that time. Therefore we
started a randomized, multicentre EORTC trial in 1980: comparing
BCT with MRM for patients with tumours up to 5 cm and axillary
node negative or positive disease. From the 868 patients most
had stage II disease, 80% of them had a tumour sized between
2.1 and 5 cm [7,8]. BCT comprised of lumpectomy with an
attempted margin of 1 cm of healthy tissue and complete axillary
clearance, followed by radiotherapy to the breast of 50 Gy in
5 weeks and a boost dose to the tumour bed of 25 Gy. The initial
results showed that MRM resulted in better local control than
BCT, but this did not affect overall survival or time to distant
metastases. After evaluating the psychological and cosmetic effects
we concluded that body image in the BCT group was significantly
more positive than in the MRM group. Patients treated with BCT
350 The changing landscape in radiotherapy for breast cancer: Lessons from long term follow-up in some European breast cancer trialseven had less fear of recurrence of the cancer and would, if neces-
sary, choose the same treatment again [9]. After a long term
follow-up of 22.1 years there was still an increase of the local
recurrence rate in the BCT patients. (Addendum Fig. A2). Neverthe-
less BCT and mastectomy resulted in similar survival and distant
metastases rates in a trial, with mainly stage II breast cancer
patients. There was also no difference between the groups in time
by age (Fig. 3) [8]. These long-term trial results -with similar sur-
vival results after BCT or after mastectomy- are in line with the
meta-analysis of the EBCTCG [10]. This led us to conclude that
BCT including radiotherapy, offered as standard care to patients
with early breast cancer seems to be justified for patients with
stage I and II disease with tumours up to 5 cm with equal efficacy
in patients younger or older than 50 years of age.
Boost versus no Boost, EORTC trial 22881 and the Young Boost
trial
The equal survival after BCT or mastectomy led us to consider
whether reduction of the treatment intensity was possible by low-
ering the radiation boost dose. Especially as there was some con-
cern about the worse outcome of cosmesis in some patients
treated within the 10801 trial. A boost dose of 16 Gy was compared
with no boost after whole breast irradiation, instead of the 25 Gy
boost as used in the 10801 trial. More than 5000 patients with
microscopically complete excision for invasive disease followed
by whole-breast irradiation of 50 Gy in 5 weeks were randomized
to receive a 16 Gy boost or no boost ClinicalTrials.gov,
NCT02295033). The main purpose of this study was to analyse
which subgroups of patients would benefit from a higher radiation
dose, and whether local control would affect survival. At 10 years of
follow-upwe found that a boost dose of 16 Gy led to improved local
control in all age groups, the benefit of the boost was observed in all
tumour types and histological grades (Fig. 4, Addendum Fig. A3)
[11,12]. Patients younger than 50 years of age at time of diagnosis
mostly profited from this higher radiation dose. Remarkably, in
the final analysis after 20 years of follow-up local control curves
are continuously separated in all age groups. In case of ipsilateral
breast tumour recurrence in the majority of patients mastectomies
as first salvage treatment were applied, probably explaining why
there was no difference in survival despite the improvement of
local control by giving a boost dose [13].
We concluded therefore a radiation boost after whole-breast
irradiation has no effect on long-term overall survival, but can
improve local control, although it increases the risk of moderate
to severe fibrosis (cumulative incidence 30.4% vs 15%). The largestFig. 3. Survival after mastectomy or breast conserving therabsolute benefit was seen in young patients and fortunately the
increase in fibrosis was independent of age. The benefit of the extra
radiation dose in older patients was limited and a boost dose can
therefore be avoided in most patients older than age 60 years. To
estimate the benefit of a boost dose on local control in individual
patients on beforehand, we developed a nomogram for local con-
trol and fibrosis [14,15].
The association of pathological prognostic factors with local
control was studied in a separate analysis. It showed again that
young age and the presence of DCIS adjacent to the invasive
tumour increased the risk of local recurrence. In patients with both
prognostic factors the boost reduced the risk with an HR of 0.37,
leading to an absolute risk reduction of 16% at 20 years. This
analysis showed that even after 5 years of follow up the local
recurrence rate continued to increase in patients with adjacent
DCIS, with further separation of the curves (Fig. 5). Surprisingly
the impact of high grade malignancy decreased over time. This
underlines the importance of long-term follow-up to correctly esti-
mate absolute effects in patients with breast cancer [16]. Similarly
Laurberg et al. showed that with longer follow up there is a contin-
uous increase in local recurrence after BCT, which even seems to
affect the survival in young patients [17].
In an attempt to further improve the local recurrence rate in
young patients a dose escalating trial was initiated: ‘‘Young Boost”
trial clinicaltrials.gov; NCT00212121. The main objectives were to
compare the effect of a high boost dose (26 Gy) with a low boost
dose (16 Gy) in breast conserving therapy on the local recurrence
rate and cosmesis, and secondly to test the genotypic and pheno-
typic profiles of breast tumours in young patients with invasive
breast cancer and its relation to local recurrence after BCT and their
radiosensitivity. The trial has already been completed with an
accrual of more than 2400 patients. The trial outcome will be anal-
ysed at 10 years follow up in 2020.
Preoperative accelerated partial breast irradiation (PAPBI)
To further reduce the treatment burden accelerated partial
breast irradiation (APBI) has been advocated as an alternative to
whole breast irradiation (WBI) for early stage breast cancer in
elderly women. ABPI can be delivered by three-dimensional con-
formal external-beam radiation, but large inter-observer variabil-
ity in defining the tumour bed postoperatively has been shown.
This is becoming even more complicated because of the increased
use of oncoplastic surgery, leading to larger irradiated volumes
[18]. This uncertainty can be overcome by giving radiotherapy
before surgery which also allows us to measure the tumourapy by age. EORTC trial 10810. Adapted from Ref. [8].
Fig. 4. Cumulative incidence of ipsilateral breast cancer recurrence according to age. Age (A) 40, (B) 41 to 50, (C) 51 to 60, and (D) 60 years. HR, hazard ratio; O, occurrences;
N, number of patients at risk. Adapted from Ref. [12].
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biomarkers. We anticipated that this approach may avoid the
development of breast induration/fibrosis and worse cosmetic out-
come, as seen in Canadian trial [19], due to the fact that with sur-
gery the irradiated high dose area is removed. We therefore
initiated a multi-centre preoperative accelerated partial breast
irradiation phase II trial (PAPBI) ClinicalTrials.gov, NCT01024582.
Low risk patients of 60 years and older were preoperatively irradi-
ated with IMRT instead of postoperative radiotherapy. The main
objective was to investigate the impact of a short fractionated
schedule given preoperatively on local control, cosmesis and breast
fibrosis. The first results on 70 patients treated in our PAPBI trial
show low complication rates, limited fibrosis in a small volume
and good–excellent cosmetic results. In contrast to what was seen
in the boost trials, in which the cosmetic results diminished during
follow-up. In the PABPI trial the cosmetic results improve with
longer follow-up. We concluded therefore that preoperative PBI
is a feasible and widely available technique with promising results
for a selected group of patients [18]. In these patients Sophie
Bosma found important differences in the gene profiles before
and after irradiation with whole genome analysis. Horton et al.
reported a similar approach but with a dose escalating phase I
study using one single fraction of radiation in 32 patients [20].
They concluded that their single dose preoperative irradiation is
feasible in breast cancer and has the potential to challenge the cur-
rent treatment paradigm and provide a path forward to identify
radiation response biomarkers. Our phase II study is now com-
pleted with 137 patients. The feasibility of our phase II trial formedthe basis for a randomized phase III trial Clinicaltrials.gov:
NCT02913729 comparing pre- versus postoperative partial breast
irradiation. The goal is to assess the cosmetic effect in female
patients aged 51 years or older with early stage breast cancer. An
additional goal in this study is to assess tumour response to radio-
therapy and to identify biomarkers in order to design more individ-
ualized treatment strategies for breast cancer patients treated with
breast conserving therapy.Predictive markers for local recurrences after BCT?
Gene expression profiling has been successfully applied to dis-
tinguish molecular subtypes in breast cancer and to predict the risk
of metastasis and overall survival [21,22]. More recently, gene
expression profiling has also been used in trying to identify signa-
tures predicting response to neoadjuvant chemotherapy and the
benefit of chemotherapy in early breast cancer [23,24]. In addition,
gene expression profiling of primary breast carcinomas using
microarray technology has already been used to discover a signa-
ture associated with a higher risk of true local recurrence after
BCT. However, results have been contradictory. With Nuyten we
suggested that the wound signature could identify subgroups of
patients being at increased risk of developing a local recurrence
after BCT [25]. He was followed by Kreike;, he could not confirm
the wound response signature and other classifiers in a series of
165 young (650 years old) premenopausal Dutch patients. Kreike
constructed a local recurrence classifier based on the expression
Fig. 5. Local recurrence in patients with invasive breast cancer in and adjacent DCIS. Adapted from Ref. [16].
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of 161 consecutive patients who underwent BCT using a different
microarray platform [26]. This classifier was mostly characterized
by proliferation but did not yield a significant independent addi-
tive value as young age remained the sole predictive factor of local
recurrence in multivariate analysis. Servant and colleagues there-
fore tried to validate the 111-gene classifier proposed by Kreike
in a well-characterized data set of 343 patients [27]. They were
unable to validate this classifier or to define a strong classifier for
local relapse after BCT superior to clinical variables. Tramm et al.
identified and validated a DBCG-RT 7 gene profile, identifying
patients with very low risk of a local recurrence and no benefit
from post-mastectomy radiotherapy [28]. A follow-up study indi-
cated that this prognostic and predictive effect of the DBCG-RT
profile was independent of intrinsic subtype, regardless of which
method was used for determining the molecular subtypes [29].
Eschrich and colleagues developed a radiosensitivity molecular
signature (radiosensitivity index) and validated their radiosensitiv-
ity index in 2 independent breast cancer data sets. Although, this
radiosensitivity molecular signature did predict distant metas-
tases, an impact on locoregional breast recurrences could not be
determined in their breast cancer data sets [30]. Recently, studies
of the 21-gene Oncotype DX and 70-gene signature MammaPrint
suggested these assays can identify patients with a high risk of
locoregional recurrence after mastectomy or BCT, although they
cannot distinguish between patients who should benefit frommas-
tectomy or BCT [31,32]. Speers and colleagues developed a molec-
ular signature for radiation response in breast cancer that is
enriched for biologic concepts implicated in response to radiation
therapy, including DNA damage repair and cell cycle regulation
[33]. Their validation suggested that their signature outperforms
previous signatures and may more accurately stratify the likeli-
hood of local recurrence of breast cancer. These uncertainties in
predicting the treatment outcome of irradiated patients with
breast cancer suggest the need for validating the assays described
in major trials such as the ‘‘Young Boost” trial clinicaltrials.gov;NCT00212121 which has just been completed. The results of this
randomized trial will hopefully lead to a validated gene profile pre-
dicting which patients <51 years benefit from a higher dose and
which patients are radiation resistent and for whom other treat-
ment options are a better choice. The major advantage of the afore-
mentioned assays is the fact that these data sets are now available
online and can be tested in an independent manner on material
from trial patients. Based upon the whole genome analysis from
the PAPBI phase II and III trial, which provide information about
radiosensitivity in vivo, and the RNA sequencing studies of patients
with a local recurrence in the Young Boost trial we hope to estab-
lish a radiosensitive gene signature.
Discussion
The trials described here reflect major changes in the intensity
of treating patients with breast cancer that have occurred during
the last decades, starting with obtaining tumour control with
radiotherapy for locally advanced breast cancer whether or not
in combination with systemic therapy. Subsequently the possibil-
ity of breast conserving therapy by demonstrating equal survival
after mastectomy or breast conserving therapy, despite a few more
local failures after BCT. Furthermore the additional benefit of adju-
vant systemic treatment by improving local control after radio-
therapy which was seen in the locally advanced breast cancer
trial and in the boost no boost trial. The boost vs no boost trial
showed that especially young patients were at high risk for a local
recurrence, fortunately a boost dose of 16 Gy appeared beneficial
in these young patients. The long term follow-up of the boost vs
no boost trial showed the possibility of reducing the treatment
intensity by omitting the boost dose in selected groups of patients,
without harming the survival. The lack of impact on survival,
despite a higher local recurrence rate in the no boost group, may
be explained by the efficacy of salvage mastectomy in the majority
of patients with a local recurrence, whether or not combined with
adjuvant systemic treatment.
Fig. A1. Reversal of fortune: survival curves during follow up after treatment for locally breast cancer with Radiotherapy alone or in combination with hormones and or
chemotherapy (adapted from Ref. [1]) A1a Survival for adjuvant chemotherapy at trial closure, and five years after trial closure, A1c Survival for adjuvant hormonotherapy 5b
years after trial closure.
Fig. 6. Local Recurrence rate in three BCT trials with early breast cancer from 1980 till 2016. Updated from Refs. [8,12].
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354 The changing landscape in radiotherapy for breast cancer: Lessons from long term follow-up in some European breast cancer trialsThe higher local recurrence rate in younger patients was the
mean reason for a special trial for with intensified treatment by
delivering a higher radiation dose in a randomized set up. Although
the trial results are not yet unblinded it is obvious that there is a
major improvement in local control in this young patient group
as a whole when compared with the previous trials results
(Fig. 6). These low local recurrence rates after BCT are also reported
by others [34]. This brings us to the limitations of older trials, as
the present results are certainly different from the past ones. The
better results are probably reflecting a change in treatment policy
on different levels, like better surgical and radiotherapy treatment
techniques, improved radiological and pathological methods and
reporting the increased application of systemic treatment, and
more effective systemic treatments including targeted anti Her-2
neu treatment. Another explanation may be a major shift in patient
population as a result of screening and better public awareness,
leading to more elderly patients with grade 1 tumours ER
+ tumours treated with BCT although this is not the case for the
patients under 50 years of age. This means that the outcome of
older trials cannot directly be translated to the patient seen nowa-
days, but the changing environment should be taken into account.
At the same time the strength of the older trials is the long term
follow-up. They demonstrated the impact of hormonal therapy
on survival. They demonstrated a better local control can be
achieved in early breast cancer by intensifying the treatment, but
this came with a price; reduced cosmetic outcome. Of note these
long term data demonstrated that risk factors may change in time:
high grade tumours have an increased local recurrence risk only
during the first 5 years of follow up, while in patients with adjacent(years
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Fig. A2. Kaplan–Meier curves for a: overall survival, b: distant metastases, c: local contro
after breast-conserving therapy (BCT) and mastectomy. O = observed, N = number of patDCIS a continuous increase of local recurrences is seen during
follow-up [16]. Nevertheless, the impact of a boost dose remains,
even a further separation of the curves was observed after 5 year
follow-up, especially in patients with DCIS adjacent to the invasive
tumour (Fig. 5). It therefore underlines the importance of long term
trial follow-up to correctly estimate absolute effects in patients
with breast cancer.
This article focus mainly on the impact of lessons derived from a
few selected trials. Other improvements aimed at reduction of the
treatment burden and toxicity will therefore not be discussed.
These include IMRT and image guided breath hold treatment, to
spare the skin heart and lungs [35,36], the use of shorter treatment
schedules and avoidance of radiation in older women with early
breast cancer [37,38]. Partial breast irradiation (PBI) with IORT,
implants or external irradiation is more and more used to limit
the irradiated breast volume, and sparing heart and lungs [39].
The increased rate of early breast cancer patients as mentioned
above related to increased use of mammography screening suggest
that an increasing significant proportion of patients will never
develop any clinical symptoms of breast cancer and therefore
should be considered as overtreated. In addition, local control rates
especially in older patients are very high. To address this situation,
it is even more important nowadays to develop assays to predict
the radiation response to determine which patient will benefit
from irradiation in combination with surgery. Some trials in Eur-
ope and the USA have already started to investigate withholding
radiotherapy in favourable cases, whether or not based upon
molecular subtyping. By giving preoperative partial breast irradia-
tion in a research setting tumour samples are compared before and(years
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Fig. A3. Age dependent local recurrence rate after BCT. Adapted from Ref. [11].
H. Bartelink / Radiotherapy and Oncology 121 (2016) 348–356 355after irradiation to identify imaging and genomic markers of radi-
ation response [18,21]. Hopefully this will lead to a more selective
and individualized use of radiotherapy and finding targets for com-
bined radiotherapy and novel targeting drugs.
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